Key result
This review provides an overview of enterovirus D68 epidemiology, clinical presentations, diagnostic methodologies, treatment strategies, and outbreak management.
This review provides a comprehensive overview of enterovirus D68 epidemiology, clinical presentation, and management strategies following recent global outbreaks.
Answers are grounded in this paper and cite their sources.
EV-D68 outbreaks warrant pediatric respiratory and AFP surveillance; leaves open specific antivirals and vaccines.
Following its discovery in California in 1962, enterovirus D68 (EV-D68) was reported only sporadically around the world. In August 2014, a marked increase of EV-D68 cases in young children with severe respiratory infections was reported in the USA and Canada and later in Europe and Asia. Some of these cases were also found to be associated with acute flaccid paralysis, which exacerbated public health concern, and has since triggered international efforts to strengthen both EV-D68 and acute flaccid paralysis surveillance systems. This review summarizes the current knowledge on EV-D68, offering an overview of EV-D68 epidemiology, clinical presentations, diagnostic methodologies, and treatment strategies, as well as surveillance and outbreak management.
No takes yet. Share an insight, caveat, or question.
Milhano et al. (2018) conducted a review in Enterovirus D68 (EV-D68) infection. This review provides an overview of enterovirus D68 epidemiology, clinical presentations, diagnostic methodologies, treatment strategies, and outbreak management.
Synapse has enriched 10 related papers. Consider them for comparative context: